---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-007139"
form_type: "8-K"
ticker: "FHTX"
cik: "0001822462"
company_name: "Foghorn Therapeutics Inc."
filed_at: "2023-03-09T23:59:59+00:00"
generated_at: "2026-06-18T07:34:19.396110+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Foghorn reports FY2022 net loss $108.9M; cash $345.8M; pipeline data expected H1 2023

## Summary
- Net loss $108.9M for FY2022; R&D expenses $105.6M, collaboration revenue $19.2M.
- Cash, equivalents and marketable securities $345.8M as of Dec 31, 2022; runway into H2 2025.
- Phase 1 data for FHD-286 in mUM expected H1 2023; AML/MDS clinical hold update H1 2023.
- Phase 1 data for FHD-609 in synovial sarcoma expected mid-2023.
- Newly disclosed selective EP300 degrader targeting CBP mutant cancers; potential for >100K patients/year.

## SEC filing metadata
- accession: 0001628280-23-007139
- form_type: 8-K
- ticker: FHTX
- cik: 0001822462
- company_name: Foghorn Therapeutics Inc.
- filed_at: 2023-03-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/0001628280-23-007139-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/fhtx-20230307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-007139
- JSON: https://secwatch.observer/filing/0001628280-23-007139.json
- Plain text: https://secwatch.observer/filing/0001628280-23-007139.txt

## Key facts
- Governance Changes
  Foghorn Therapeutics Inc.: Amended and restated bylaws to address universal proxy rules under Rule 14a-19 (effective 2023-03-07).
  - Change: bylaw amendment
  - Effective: 2023-03-07
  source text: On March 7, 2023, in connection with the effectiveness of new Securities and Exchange Commission rules regarding universal proxy cards and a periodic review of the Company's bylaws, the Company's board of directors approved and adopted amended and restated bylaws (the “Amended and Restated Bylaws”), which became immediately effective.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1822462/000162828023007139/0001628280-23-007139-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.